Search

In patients with resected pancreatic ductal adenocarcinoma, alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency genes were associated with favorable prognoses.

… Thursday, July 16, 2020 In patients with resected pancreatic ductal adenocarcinoma (PDAC), alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency (HRD) genes were associated with favorable prognoses, according to a study by our research

A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.

… Friday, August 24, 2012 Summary A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs. Cancer experts have long known that virtually all cancers

A Q&A with MSK Urologic Surgeon Richard Matulewicz, MD, MSCI, MS.

… Monday, September 9, 2024 Since 2013, MSK has offered primary retroperitoneal lymph node dissection (RPLND) to select patients with low-volume incident or relapsed seminoma metastatic only to the retroperitoneum, in lieu of the traditional standards of care which were previously chemotherapy or radiation

Hear from Memorial Sloan Kettering breast surgical oncologist Tracy-Ann Moo about her experience as a woman of color in medicine.

… Wednesday, February 10, 2021 In honor of Black History Month, we spoke with Memorial Sloan Kettering breast surgical oncologist Tracy-Ann Moo about the challenges of being a person of color in medicine — especially in the age of COVID-19. The most recent data from the Association of American Medical

Investigators at MSK are developing new immunotherapy treatments that rely on engineering T cells to recognize mutated proteins that are unique to cancer.

… Friday, April 29, 2022 Immunotherapy is an increasingly important form of cancer treatment. It encompasses a class of cancer therapies that harness the immune system’s natural ability to recognize and eliminate tumor cells. Most immunotherapies work by boosting the power of a type of white blood cell

Learn about seven nursing staff members were honored with a Robbins Family Award for Nursing Excellence.

… Thursday, October 1, 2020 Andrea Smith Excellence in Nursing Leadership — Andrea Smith (Nurse Leader, Outpatient Nursing Services, Evelyn H. Lauder Breast Center) Leon Chen Excellence in Advanced Nursing Practice — Leon Chen (Nurse Practitioner, Critical Care, Intensive Care Unit) Jessica Agostini Excellence

Memorial Sloan Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research.

… Thursday, January 17, 2013 Memorial Sloan Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research. In this role, Dr. Sabbatini will streamline and accelerate the clinical research process while ensuring

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.

… Monday, January 22, 2018 When the Tri-Institutional Therapeutics Discovery Institute launched just over four years ago, nothing like it existed in academia. The nonprofit academic corporation – a joint venture between Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell

Animal model research from MSK has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.

… Friday, June 14, 2024 Periods of fasting reprogram the immune system’s natural killer cells to better fight cancer, according to a new study in mice from researchers at Memorial Sloan Kettering Cancer Center (MSK). Fasting and other dietary regimens are increasingly being explored as ways to starve cancer

Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.

… Monday, January 29, 2018 Summary Doctors at MSK are at the forefront of developing treatment strategies that target the androgen receptor. This hormone drives the growth of many triple-negative breast cancers. For many people with breast cancer , drugs that target proteins driving the cancer’s growth